Skip to content

Internet Buzzing (November 26, 2012) About Exelisis’ Orphan Drug Cabozantinib For Medullary Thyroid Cancer

November 27, 2012

       The Internet is buzzing about Exelisis’ orphan drug Cabozantinib for Medullary Thyroid Cancer (MTC) and the upcoming November 29, 2012, FDA PDUFA date : 

1)  Bio-Wire.com November 26, 2012 article titled, “Exelixis Traders Brace For Upcoming FDA Decision” 

2)  StreetInsider.com November 26, 2012 article titled, “Analysts, Physicians Positive on FDA Approval of Exelixis’ Cabozantinib into Meeting”  

3)  DailyFinance.com November 26, 2012 article titled, “What’s Taking So Long to Approve This Drug ?”  

4)  TheStreet.com November 26, 2012 article titled, “Exelixis Preps for Thyroid Cancer Drug Approval”  

5)  NASDAQ.com November 26, 2012 article titled, “Awaiting The Last Word on Exelixis’ EXAM”  

         CafePharma.com, a website for pharmaceutical and medical sales professionals, has a “Social Media Monitoring Page for Exelixis” which has the following statistics : 

–          # of Twitter tweets in the last 24 hours = 49

–          Average Twitter tweets per    24 hours =   6.  

References 

Orphan Druganaut November 25, 2012 Blog Post titled, “Why is November 29, 2012 Important For Exelixis’s Orphan Drug Cabozantinib for Medullary Thyroid Cancer ?”  

Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: